The Company has completed its De-bottlenecking/ Re-engineering project for its Ibuprofen manufacturing facilities at Barnala with project cost of
24 Crores and commenced the enhanced production from today i.e 19 November 2015. Post this completion, the capacity of Ibuprofen plant increased to 6200 TPA .
The Ibuprofen manufacturing facilities have been approved by US Food and Drug Administration (USFDA), ANVISA, EDQM, WHO & MOH Japan. The Company is already exporting its Ibuprofen in regulated & Emerging markets i.e. Europe, Latin America, Middle East, etc and with the recent approval from USFDA, the company is expanding its business of Ibuprofen in USA.